Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Carolyn J, Bowen"'
Autor:
S J Kathman, J.S. de Bono, Mohammed M. Dar, Carolyn J. Bowen, Mark R. Middleton, D D Williams, Miranda Payne, Sarah P. Blagden, L. R. Molife, J. P. Hodge, Andrew Protheroe, L S Vasist, Alison Reid, A Seebaran
Publikováno v:
British Journal of Cancer
The aim of this study is to define the maximum tolerated dose (MTD), safety, pharmacokinetics (PKs) and efficacy of ispinesib (SB-715992) in combination with docetaxel. Patients with advanced solid tumours were treated with ispinesib (6-12 mg m(-2))
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595564b236ce6525445003d1cd45e7b3
https://doi.org/10.1038/sj.bjc.6604264
https://doi.org/10.1038/sj.bjc.6604264
Autor:
Jung Wook Park, Alicia J. Allred, Mary Beth Wire, Carolyn J. Bowen, Daphne Williams, Bin Peng, Edmund J.D. Lee
Publikováno v:
British Journal of Clinical Pharmacology. 72:321-329
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • OATP1B1 is important for hepatic uptake of rosuvastatin and BCRP is important for rosuvastatin absorption and elimination. Eltrombopag inhibits OATP1B1 and BCRP in vitro at clinically relevant concentratio
Autor:
Gemma M. Matthys, Jung Wook Park, Bin Peng, Mary Beth Wire, Sandra McGuire, Daphne Williams, Julian Jenkins, Carolyn J. Bowen
Publikováno v:
The Journal of Clinical Pharmacology. 51:301-308
This was a double-blind, placebo-controlled, randomized, parallel, dose-escalation study to assess the pharmacokinetics, platelet response, safety, and tolerability of supratherapeutic doses of eltrombopag (100 mg, 150 mg, and 200 mg once daily) admi
Publikováno v:
Photodermatology, Photoimmunology & Photomedicine. 26:243-249
Background/purpose: Eltrombopag is an oral, small molecule, thrombopoietin receptor agonist approved in the United States for the treatment of chronic immune thrombocytopenic purpura and under investigation for treatment of thrombocytopenia due to ot
Autor:
Mohammed M. Dar, Suresh Ramalingam, Jennifer Volkman, Kyle D. Holen, George Wilding, Chandra P. Belani, J. P. Hodge, Carolyn J. Bowen, Peter T.C. Ho, Lakshmi S. Vasist, Ramesh K. Ramanathan
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:447-454
To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory l
Autor:
Bin Peng, Jianping Zhang, Daphne Williams, Jung Wook Park, Julian Jenkins, Carolyn J. Bowen, Sandra McGuire, Mary Beth Wire, Gemma M. Matthys
Publikováno v:
British Journal of Clinical Pharmacology. 70:24-33
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Some non-anti-arrhythmic drugs delay cardiac repolarization, which can be measured as an increase in the QT interval. Delays in cardiac repolarization create an electrophysiological environment that favours th
Autor:
Steve Mangum, Phillip A. DeSimone, Michael Doukas, Aimee K. Bence, Andrew G. Stead, Kevin M. Koch, Carolyn J. Bowen, Eric B. Anderson, George A. Davis, Deborah A. Smith, Maqbool A. Halepota, Val R. Adams, Showchien Hsieh, Neil L. Spector
Publikováno v:
Investigational New Drugs. 23:39-49
GW572016 is a dual EGFR-ErbB2 inhibitor that has promise as an anticancer agent. Two phase I studies were conducted to determine the safety, tolerability and pharmacokinetics of single and multiple doses given to healthy subjects. The single dose stu
Autor:
Frances Gorycki, Mark A. Levy, Ernest M. Schubert, Jung Wook Park, Peter D. Gorycki, Mary Beth Wire, Yanli Deng, Daphne Williams, Armina Madatian, Carolyn J. Bowen, Bin Peng
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 39(9)
The metabolism and disposition of eltrombopag, the first-in-class small molecule human thrombopoietin receptor agonist, were studied in six healthy men after a single oral administration of a solution dose of [(14)C]eltrombopag (75 mg, 100 μCi). Elt
Autor:
Dan Mulkerin, Mohammed M. Dar, Noelle K. LoConte, Ronald A. Fleming, Kyle D. Holen, Carolyn J. Bowen, Trevor W. Dennie, Dona Alberti, Katherine Oliver
Publikováno v:
Clinical colorectal cancer. 10(1)
Background Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related mortality in the United States, and new treatment options are needed. This phase I study investigated a novel regimen combining 2 chemotherapy drugs with proven effic
Publikováno v:
Photodermatology, photoimmunologyphotomedicine. 26(5)
Eltrombopag is an oral, small molecule, thrombopoietin receptor agonist approved in the United States for the treatment of chronic immune thrombocytopenic purpura and under investigation for treatment of thrombocytopenia due to other etiologies. In v